Human lactoferrin induces asthmatic symptoms in NC/Nga mice

Kenjiro Nagaoka¹*, Tatsuo Ito¹*, Keiki Ogino¹, Eri Eguchi¹ & Yoshihisa Fujikura²

1 Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
2 Department of Molecular Anatomy, Faculty of Medicine, Oita University, Oita, Japan

Abstract

Lactoferrin in commercial supplements is known to exert anti-viral and anti-allergenic effects. However, this is the first study to evaluate the induction of allergic airway inflammation in NC/Nga mice. Human lactoferrin was administered intraperitoneally with aluminum oxide for sensitization. Five days later, lactoferrin was inoculated intranasally for 5 days, and then on the 12th day, the single inoculation of lactoferrin intranasally was performed as a challenge. On the 13th day, airway hypersensitivity was assessed (AHR), a bronchoalveolar fluid (BALF) cell analysis was conducted, serum IgE and serum lactoferrin-specific IgG and IgE levels as well as the mRNA expression levels of cytokines and chemokines in the lung were measured, and a histopathological analysis of the lung was performed. Human lactoferrin increased AHR, the number of eosinophils in BALF, serum lactoferrin-specific IgG levels, and the mRNA levels of IL-13, eotaxin 1, and eotaxin 2. Moreover, the accumulation of inflammatory cells around the bronchus and the immunohistochemical localization of arginase I and human lactoferrin were detected. Collectively, these results indicate that human lactoferrin induced allergic airway inflammation in mice. Therefore, the commercial use of human lactoferrin in supplements warrants more intensive study.

Introduction

Lactoferrin in supplements is known to exert anti-bacterial and anti-viral effects. Lactoferrin is one of the main proteins found in the breast milk of humans and cows and has been detected in various tissues including neutrophil, secondary granules, lacrimal fluid, colostrum, saliva, and mucosal secretions (Ward et al. 2005). Lactoferrin is an 80-kDa iron-binding glycoprotein (Lönnrdal and Iyer 1995), belongs to the transferrin family, and has various functions such as the scavenging/transport of iron, stimulation of neutrophil aggregation (Oses et al. 1981), inhibition of eosinophil migration (Bournazou et al. 2010), generation of superoxide (\(O_2^-\)) by eosinophils (Thomas et al. 2002), enhancement of NK cell activity (Damiens et al. 1998), inhibition of intestinal immune responses (Li et al. 2014), and anti-cancer effects (Deng et al. 2013).

Previous studies reported that lactoferrin ameliorated the severity of allergies and inflammation (Wang et al. 2013; Hill and Newburg 2015; Giansanti et al. 2016). The amelioration of inflammation has been attributed to decreases in the generation of \(O_2^-\) (Britigan et al. 1994) and the down-regulated expression of TNFα (Baveye et al. 1999), IL-1β (Legrand et al. 2004), and IL-6 and IL-8 (Zimecki et al. 1998). However, native human lactoferrin
had antigenicity in mice and generates specific IgG, in which iron binding capacity or its glycosylation may contribute to its antigenicity (Almond et al. 2012, 2013). When lactoferrin from human or other animal origins is administered into blood or mucosal tissue, it may become an allergen. Previous studies demonstrated the anti-asthmatic or anti-inflammatory effects of lactoferrin, and this study is the first to demonstrate the induction of allergic airway inflammation through the nasal inoculation of NC/Nga mice, which are hypersensitive to mite allergens, with human lactoferrin. We also described the mechanisms underlying allergic airway inflammation in mice in detail.

**Materials and Methods**

**Animals**

Male NC/Nga mice (7 weeks old, seven mice/group) were purchased from Charles River Laboratories Japan (Yokohama, Japan). Mice were maintained under specific pathogen-free conditions with a 12-h light/dark cycle and had free access to a standard diet and tap water. They were acclimatized for at least 1 week before experiments. The care and handling of mice were in accordance with the Guidelines for the Care and Use of Laboratory Animals at the Shikata Campus of Okayama University and approved by the Okayama University Institutional Animal Care and Use Committee.

**Induction of asthma**

Mice were sensitized using intraperitoneal injections of 50 μg human lactoferrin (Sigma, St. Louis, MO) mixed 1:1 with 100 μL Imject Alum (Thermo Scientific, Rockford, IL) on days 0 and 1. This was followed by the intranasal administration of 50 μg human lactoferrin in 25 μL saline under anesthesia with 40 mg/kg sodium pentobarbital (Kyoritsu Seiyaku, Tokyo, Japan) on days 6–10. On day 16, 50 μg human lactoferrin was intranasally administered as a challenge. Instead of human lactoferrin, saline was used as the control group. A schematic protocol is shown in Figure 1.

**Analysis of airway hyperresponsiveness**

Analysis of airway hyperresponsiveness (AHR) to acetylcholine (ACh) was measured on day 17, as described previously (Shibamori et al. 2006). Briefly, mice were anesthetized with pentobarbital and connected to an artificial ventilator through a surgical incision in the trachea. A pulmotor system, conducted with a rodent ventilator (Respirator model SN-480-7; Shimano Manufacturing Co., Ltd., Tokyo, Japan), was connected to ventilated mice (0.7 mL/stroke, 60 strokes/min). Spontaneous respiration was inhibited by an intravenous injection of gallamine triethiodide (350 μg/mouse, Sigma), followed by the intravenous administration of ACh with stepwise increases in concentration from 62.5 to 4000 μg/kg. Bronchoconstriction was expressed as a percentage of the maximum overflow volume by completely occluding the tracheal cannula.

**Analysis of cells in bronchoalveolar lavage fluid**

Briefly, bronchoalveolar lavage fluid (BALF) was collected with 1.0 mL of saline using a trachea cannula after the analysis of AHR. BALF was centrifuged, and cell pellets were resuspended in 1 mL of PBS. Total BALF cell counts were obtained with a hemocytometer and placed on slides with Cytospin. Slides were fixed under natural air, and

---

![Figure 1. Schematic representation of the experiment. Each mouse group received the mixture with alum intraperitoneally on days 0 and 1. On days 6–10 and 16, intranasal administration was performed. 50 μg of human lactoferrin was dissolved in saline.](image-url)
cells were stained with Wright-Giemsa. A blind observer assessed the percentage of BALF cells (macrophages, eosinophils, neutrophils, and lymphocytes) on each slide by counting a minimum of 200 cells in random high-power fields with a light microscope (Takemoto et al. 2007).

**Quantitative real-time PCR (qRT-PCR) analysis**

Total RNA was isolated from the lungs using ISOGEN (Nippon Gene, Tokyo, Japan). Oligo(dT)-primed reverse transcription was performed using 1 μg total RNA with a 1st strand cDNA synthesis kit (TaKaRa Bio, Kyoto, Japan) according to the supplier’s protocol. A real-time PCR analysis was performed using StepOnePlus (Applied Biosystems, Foster City, CA). The primer sequences used are shown in Table 1. GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) was used as an internal control (Ogino et al. 2014, 2016).

**Plasma IgE and human lactoferrin specific-IgE and IgG levels**

The IgE levels in plasma were measured using a mouse IgE ELISA kit (Morinaga Institute of Biological Science, Yokohama, Japan). The levels were quantified by the standard in the kit and detection limit was 0.5 ng/mL.

In order to detect human lactoferrin specific-IgE and IgG, we performed ELISA as described previously (Shibamori et al. 2006). Briefly, microwell plates were coated with 2 ng/100 μL/well of human lactoferrin and incubated at 4°C overnight. After blocking with PBS containing 5% FBS, sections were incubated in 5% normal goat serum. Specimens were incubated at 4°C overnight with polyclonal antibodies against arginase I (1:50) and human lactoferrin (1:150). Specimens were then treated with goat anti-rabbit immunoglobulin conjugated with a peroxidase-labeled dextran polymer (Dako, North America, Carpinteria, CA) at room temperature for 1 h. Visualization was performed by adding 3,3-diaminobenzidine tetrahydrochloride (Dako) as a substrate, and counterstaining was performed with hematoxylin. Rabbit non-immunoglobulin (Dako) was used as a negative control.

In hematoxylin and eosin (H&E) staining, fixed lung tissues were dehydrated, embedded in paraffin, and sectioned to examine inflammation. Periodic acid-Schiff (PAS) staining was also performed to assess goblet cell hyperplasia, and this was followed by Azan staining to

**Table 1. Primers used for Quantitative real-time PCR.**

| Target gene | Sense primer (5’ to 3’) | Antisense primer (5’ to 3’) |
|-------------|-------------------------|-----------------------------|
| GAPDH       | AGGTCGGTGTGAAAGGGATTGG  | TGTAGACCATGATGTTGAGGTTCA    |
| IFN-γ       | ATGAACTGCACACACGATC     | CCATCTTTTGCCCAGTCTCTCCT    |
| IL-1β       | GCAACTGTTCTGAAACTCAACT  | ATCTTTTGGTTCGTCGCAACT      |
| IL-4        | TAGAAGGTCAAGGAGAACGAA   | CGAGTCACCTTCATCTCTTTGGT    |
| IL-5        | CTGC TGACACAGCAGGAGACG   | TCTTCACTTAGAGCTAGCCCTTG    |
| IL-13       | TGTTCTTCCCTCTGACCC      | CACACTCCATACACACGTCGC      |
| IL-33       | ATGGACGGGCAATCTGGAGC    | GCGGCTGCGCTGAACTTT         |
| CCL11 (eotaxin 1) | GAAATACCAAACACACGAGTCAC  | ATCTTCGCGCAATCTCTTCT      |
| CCL24 (eotaxin 2) | AATTCCGAAAACGCAGTAGGG   | TTCTATGCGCTTCGCTTGGT     |
| ARG1        | CTCACCAACCGAACACAGTGC   | ATCTTGCGCACTACCTCTTT       |
| ARG2        | TCCCTCAGGCGCAAATTC      | GCTGACCATATTCACCTCCTA     |
| NOS1        | CTCCACGTCAGGCGGAAATTC   | GGACCTCATATCTGTTGAGG     |
| NOS2        | GTCTCTACCACCAAAATACAAGA | GTCGAGCGGTCTGATGCAC      |
| NOS3        | GACCGACCATTTGGGAAT      | CTCATGAGCCGCTGACAG       |
| MUC5AC      | CAGGACCTCTGTGGAAATCGTACC | GAAGGCTCTGACACAGGG      |
visualize collagen fibers in interstitial spaces. The levels of inflammation in peribronchial areas of the lung were estimated as described in previous study (Murakami et al. 2015) using ImageJ software (National Institutes of Health, Bethesda, MD); A value of 0, no inflammation in bronchi; a value of 1, bronchi occasional infiltrated with inflammatory cells; a value of 2, most bronchi surrounded by a thin layer (1–5 cells thick) of inflammatory cells; and a value of 3, most bronchi surrounded by a thick layer (more than 5 cells thick) of inflammatory cells. Goblet cell hyperplasia and collagen fiber were semi-quantitatively expressed using ratio of positive area by PAS or Azan staining in bronchial area.

**Purity of human lactoferrin by SDS-PAGE and western blotting**

The purity of human lactoferrin (50 ng) was assessed using SDS-PAGE with detection by silver staining (Sigma) and transferal to PVDF membranes (Millipore, Billerica, MA). After blocking with 5% dried skimmed milk in Tris-buffered saline containing 0.5% Tween 20 (TBS-T), blots were incubated with rabbit anti-human lactoferrin (1:1000) (Abcam) or mouse anti-human lactoferrin IG in plasma of mice with human lactoferrin-induced airway inflammation in this study (1:400) and a horseradish-peroxidase (HRP)-conjugated secondary antibody (1:2000 or 1:4000) (Dako). Antibody-specific bands were detected using an enhanced chemiluminescence Western blot detection system (Perkin-Elmer, Boston, MA).

**Statistical analysis**

Statistical analyses of results with two types of independent variables were performed by a two-way ANOVA (group × concentration) followed by Bonferroni’s post hoc test. In order to compare differences in two sets of data with normal distributions, a two-tailed unpaired t-test was performed. If normality tests failed, the Mann-Whitney U-test was used. Data are expressed as the mean ± standard error (SEM). P values < 0.05 were considered significant. GraphPad Prism (GraphPad Software, San Diego, CA) was used as software in statistical analyses.

**Results**

**Effects of human lactoferrin on AHR**

AHR values in the saline control group and lactoferrin group increased as ACh concentrations became higher. The two-way ANOVA showed an interaction between the concentration of ACh and the treatment group. Therefore, a one-way ANOVA was performed and revealed significant differences in bronchoconstriction values for AHR between the saline control group and lactoferrin group. Bonferroni’s multiple comparison test as a post hoc analysis showed significantly higher bronchoconstriction values against 500 μg/kg, 1000 μg/kg, 2000 μg/kg, and 4000 μg/kg ACh in the lactoferrin group than in the saline group (Fig. 2).

**Effects of lactoferrin on BALF**

Total cell numbers and the percentages of macrophages, eosinophils, neutrophils, and lymphocytes in BALF were significantly higher in mouse groups inoculated with lactoferrin than in those exposed to saline (Fig. 3).
Effects of lactoferrin on the mRNA expression of cytokines, chemokines, arginases, and nitric oxide synthases

The mRNA expression levels of several cytokines, chemokines, arginase (I, II), nitric oxide synthase (I, 2, and 3), and MUC5AC were measured using real-time PCR (Fig. 4). The mRNA expression levels of IL-4, IL-5, IL-13, IL-33, eotaxin 1, arginase I, arginase II, IL-1β, and MUC5AC were significantly higher in the lactoferrin group than in the saline control group.

Effects of lactoferrin on plasma IgE and lactoferrin-specific IgG and IgE levels

Total IgE levels were measured in the saline control group and lactoferrin group. No significant differences were observed in the plasma levels of IgE between the two groups (Fig. 5A). Specific IgE against lactoferrin was not detected in the lactoferrin or saline control group. However, specific IgG levels were significantly higher in the lactoferrin group than in the saline control group (Fig. 5B).

Effects of lactoferrin on histopathological changes in the lung

Histopathological changes in lung tissue after the inoculation with lactoferrin were shown in Figure 6. The peribronchial accumulation of inflammatory cells in the lungs was more prominent in the lactoferrin group than in the saline control group (Fig. 6A, D and G). PAS staining for goblet cell hyperplasia in bronchial epithelial cells was more intense in the lactoferrin group than in the saline control group (Fig. 6B, E and H). The number of collagen fibers around the bronchus, as revealed by Azan staining, was higher in the lactoferrin group than in the saline control group (Fig. 6C, F and I).

The immunohistochemical localization of human lactoferrin was observed in accumulated macrophages in inflammatory sites, alveolar macrophages, and alveolar lining cells (Fig. 7B), while that of arginase I was observed in inflammatory macrophages (Fig. 7D).

Purity of human lactoferrin by SDS-PAGE and western blotting

The identification of human lactoferrin was assessed by SDS-PAGE and western blotting (Fig. 8). After the
electrophoresis of 50 ng human lactoferrin, a single main protein band with a molecular weight of 80-kDa was detected in lane 2. Purified lactoferrin could be confirmed by western blotting using rabbit polyclonal anti-human lactoferrin and plasma from mice with human lactoferrin-induced airway inflammation contained human lactoferrin-specific IgG in lane 3 and 4, respectively.

**Discussion**

The results of this study demonstrated for the first time that human lactoferrin induces allergic airway inflammation in NC/Nga mice. Lactoferrin is generally considered to ameliorate the severity of inflammation and allergies (Hill and Newburg 2015; Giansanti et al. 2016), and it has been reported that the single intranasal administration improved allergic rhinitis in mice (Wang et al. 2013). However, native human lactoferrin had antigenicity and generated specific IgG against human lactoferrin in mice, in which iron binding capacity or its glycosylation may contribute to its antigenicity (Almond et al. 2012, 2013) Lactoferrin from cow milk has been correlated with the severity of atopic dermatitis (Röckmann et al. 2014). Therefore, the induction of allergic airway inflammation by human lactoferrin was anticipated.

The oral administration of bovine lactoferrin was previously shown to induce its movement from the gastrointestinal lumen to various organs in mice such as the brain, liver, kidney, and spleen by overcoming major proteolytic degradation, and induced significantly high levels of bovine lactoferrin-specific IgA and IgG (Fischer et al. 2007). Furthermore, the chronic feeding of bovine lactoferrin generated bovine-lactoferrin-containing IgA and IgG immune complexes. Immobilized lactoferrin, such as that in airway inflammatory cell surfaces, activates eosinophils, and this is followed by O$_2^-$ production, neurotoxin generation, and leukotriene C4 production via receptors for lactoferrin in eosinophils (Thomas et al. 2002). In this study, increases in the number of eosinophils in BALF may have been due to the up-regulation of mRNA for...
eosinophil-related chemokines and cytokines such as IL-4, IL-5, IL-13, and eotaxin. Although the precise mechanisms responsible currently remain unclear, the continuous inoculation of lactoferrin into the airway lumen may activate eosinophils.

The immunohistochemical localization of human lactoferrin in the lungs of mice with human lactoferrin-induced airway inflammation indicated that nasally administered human lactoferrin remains in alveolar lining cells and macrophages. There is a report that oral intake of bovine lactoferrin did not receive proteolytic process after intestinal absorption and generated immune complexes with lactoferrin-specific IgG (Fischer et al. 2007). Therefore, it is not surprising that human lactoferrin was detected in alveolar lining cells and in alveolar macrophages in human lactoferrin-induced airway inflammation in mice.

Arginase I was induced at the mRNA and protein levels in the lungs of mice with human lactoferrin-induced airway inflammation. Previous studies reported that the strong induction of arginase I with *Dermatophagoides farinae* (DF)-induced allergic airway inflammation may result in AHR (Takemoto et al. 2007; Takahashi et al. 2010). The induction of arginase I consumes L-arginine, and, thus, the generation of nitric oxide from L-arginine by nitric oxide synthase (NOS) for bronchial smooth muscle relaxation decreases because NOS uses L-arginine as a common substrate with arginase. However, it currently remains unclear whether arginase is involved in the
pathogenesis of human lactoferrin-induced allergic airway inflammation.

Previous findings on DF-induced airway inflammation implicated IL-33, which regulates Th2 cytokines, in its pathogenesis (Murakami et al. 2015). IL-33 mRNA was up-regulated in this study; therefore, IL-33 may be involved in the up-regulation of IL-13. The induction of arginase I is transcriptionally regulated by STAT6 that is under the control of IL-13R/IL-4Rx signal transductions (Yang et al. 2006; Qin et al. 2016; Valladao et al. 2016). Therefore, although the precise mechanisms underlying the induction of IL-13 and arginase I following an inoculation with lactoferrin remain unclear, human lactoferrin may stimulate IL-13 and arginase I in the lungs of NC/Nga mice.

Although total IgE levels were not enhanced in this study, specific IgG levels for human lactoferrin increased. Moreover, mice with human lactoferrin-induced airway inflammation produced immunoglobulin against human lactoferrin, as shown in Figure 8. Allergen-specific IgG, generally plays an important role in the activation and degranulation of eosinophils as well as in the manifestation of allergic disease (Kaneko et al. 1995; Oshima et al. 1996).

In this study, we demonstrated for the first time that human lactoferrin induces allergic airway inflammation in NC/Nga mice. However, we attempted the procedure similar to a method using OVA, which is not a common allergen for human. These methods used alum adjuvant to induce immune responses. To indicate the possibility of allergic airway inflammation by lactoferrin, following experiments might be needed in the future: oral administration without alum adjuvant, mice strain differences in the pathogenesis of human lactoferrin-induced airway inflammation, and comparative study using recombinant lactoferrin instead of human lactoferrin.

**Acknowledgments**

We thank R. Zhang at the Control of Innate Immunity Technology Research Association, 2217-16 Hayashi-cho, Takamatsu, Kagawa 761-0301, Japan, for her kind assistance.

**Conflict of Interest**

No potential conflict of interest relevant to this study was reported.

**References**

Almond, R. J., B. F. Flanagan, I. Kimber, and R. J. Dearman.

2012. Influence of protein expression system on elicitation of IgE antibody responses: experience with lactoferrin. Toxicology 301:50–57.

Almond, R. J., B. F. Flanagan, A. Antonopoulos, S. M. Haslam, A. Dell, I. Kimber, et al. 2013. Differential immunogenicity and allergenicity of native and recombinant human lactoferrins: role of glycosylation. Eur. J. Immunol. 43:170–181.

Baveye, S., E. Ellass, J. Mazurier, G. Spik, and D. Legrand.

1999. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin. Chem. Lab. Med. 37:281–286.

Bournazou, I., K. J. Mackenzie, R. Duffin, A. G. Rossi, and C. D. Gregory. 2010. Inhibition of eosinophil migration by lactoferrin. Immunol. Cell Biol. 88:220–223.

Britigan, B. E., J. S. Serody, and M. S. Cohen. 1994. The role of lactoferrin as an anti-inflammatory molecule. Adv. Exp. Med. Biol. 357:143–156.

Damiens, E., J. Mazurier, I. el Yazidi, M. Masson, I. Duthille, G. Spik, et al. 1998. Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumor cells. Biochim. Biophys. Acta 1402:277–287.

Deng, M., W. Zhang, H. Tang, Q. Ye, Q. Liao, Y. Zhou, et al. 2013. Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms. Oncogene 32:4273–4283.

Fischer, R., H. Debbabi, A. Blais, M. Dubarry, M. Rautureau, P. N. Boyaka, et al. 2007. Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues. Int. Immunopharmacol. 7:1387–1393.

Giansanti, F., G. Panella, L. Leboffe, and G. Antonini. 2016. Lactoferrin from milk: nutraceutical and pharmacological properties. Pharmaceuticals 9:E61.

Hill, D. R., and D. S. Newburg. 2015. Clinical applications of bioactive milk components. Nutr. Rev. 73:463–476.

Kaneko, M., M. C. Swanson, G. J. Gleich, and H. Kita. 1995. Allergen-specific IgG1 and IgG3 through Fc gamma RII induce eosinophil degranulation. J. Clin. Invest. 95:2813–2821.

Legrand, D., E. Ellass, S. Pierce, and J. Mazurier. 2004. Lactoferrin and host defence: an overview of its immune-modulating and anti-inflammatory properties. Biometals 17:225–229.

Li, Q., W. Hu, J. Zhao, J. Wang, Y. Dai, Y. Zhao, et al. 2014. Supplementation transgenic cow’s milk containing recombinant human lactoferrin enhances systemic and intestinal immune responses in piglets. Mol. Biol. Rep. 41:2119–2128.

Lönnerdal, B., and S. Iyer. 1995. Lactoferrin: molecular structure and biological function. Annu. Rev. Nutr. 15:93–110.

Murakami, I., R. Zhang, M. Kubo, K. Nagaoka, E. Eguchi, and K. Ogino. 2015. Rebamipide suppresses mite-induced asthmatic responses in NC/Nga mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 309:L872–L878.
Ogino, K., R. Zhang, H. Takahashi, K. Takemoto, M. Kubo, I. Murakami, et al. 2014. Allergic airway inflammation by nasal inoculation of particulate matter (PM2.5) in NC/Nga mice. PLoS ONE 9:e92710.

Ogino, K., K. Nagaoka, T. Okuda, A. Oka, M. Kubo, E. Eguchi, et al. 2016. PM2.5-induced airway inflammation and hyperresponsiveness in NC/Nga mice. Environ. Toxicol. 32:1047–1054.

Oseas, R., H. H. Yang, R. L. Baehner, and L. A. Boxer. 1981. Lactoferrin: a promotor of polymorphonuclear leucocyte adhesiveness. Blood 57:939–945.

Oshiba, A., E. Hamelmann, K. Takeda, K. L. Bradley, J. E. Loader, G. L. Larsen, et al. 1996. Passive transfer of immediate hypersensitivity and airway hyperresponsiveness by allergen-specific immunoglobulin (Ig) E and IgG1 in mice. J. Clin. Invest. 97:1398–1408.

Qin, Y., Y. Jiang, A. S. Sheikh, S. Shen, J. Liu, and D. Jiang. 2016. Interleukin-13 stimulates MUC5AC expression via a STAT6-TMEM16A-ERK1/2 pathway in human airway epithelial cells. Int. Immunopharmacol. 40:106–114.

Röckmann, H., M. J. van Geel, A. C. Knulst, J. Huiskes, C. A. Bruijnzeel-Koomen, and M. S. de Bruin-Weller. 2014. Food allergen sensitization pattern in adults in relation to severity of atopic dermatitis. Clin. Transl. Allergy 4:9.

Shibamori, M., K. Ogino, Y. Kambayashi, and H. Ishiyama. 2006. Intranasal mite allergen induces allergic asthma-like responses in NC/Nga mice. Life Sci. 78:987–994.

Takahashi, N., K. Ogino, K. Takemoto, S. Hamanishi, D. H. Wang, T. Takigawa, et al. 2010. Direct inhibition of arginase attenuated airway allergic reactions and inflammation in a Dermatophagoides farinae-induced NC/Nga mouse model. Am. J. Physiol. Lung Cell. Mol. Physiol. 299:L17–L24.

Takemoto, K., K. Ogino, M. Shibamori, T. Gondo, Y. Hitomi, T. Takigawa, et al. 2007. Transiently, paralleled upregulation of arginase and nitric oxide synthase and the effect of both enzymes on the pathology of asthma. Am. J. Physiol. Lung Cell. Mol. Physiol. 293:L1419–L1426.

Thomas, L. L., W. Xu, and T. T. Ardon. 2002. Immobilized lactoferrin is a stimulus for eosinophil activation. J. Immunol. 169:993–999.

Valladao, A. C., C. W. Frevert, L. K. Koch, D. J. Campbell, and S. F. Ziegler. 2016. STAT6 regulates the development of eosinophilic versus neutrophilic asthma in response to Alternaria alternata. J. Immunol. 197:4541–4551.

Wang, S. B., Y. Q. Deng, J. Ren, B. K. Xiao, Z. Chen, and Z. Z. Tao. 2013. Lactoferrin administration into the nostril alleviates murine allergic rhinitis and its mechanisms. Scand. J. Immunol. 78:507–515.

Ward, P. P., E. Paz, and O. M. Conneely. 2005. Multifunctional roles of lactoferrin: a critical overview. Cell. Mol. Life Sci. 62:2540–2548.

Yang, M., D. Rangasamy, K. I. Matthaei, A. J. Frew, N. Zimmermann, S. Mahalingam, et al. 2006. Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. J. Immunol. 177:5595–5603.

Zimecki, M., A. Właszczyk, T. Zagulski, and A. Kübler. 1998. Lactoferrin lowers serum interleukin 6 and tumor necrosis factor alpha levels in mice subject to surgery. Arch. Immunol. Ther. Exp. 46:97–104.